A Phase I Study of RP-6306 to Treat Advanced Solid Tumors with Certain Genetic Changes

Full Title

Phase 1/1b Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of lunresertib Alone or in Combination with RP-3500 or Debio 0123 in Patients with Advanced Solid Tumors (MYTHIC study)

Purpose

The purpose of this study is to find the highest dose of the investigational drug RP-6306 that can be used in advanced solid tumors containing certain genetic changes and which have come back or continued to grow despite prior treatment. 

RP-6306 blocks the protein PKMY1, which plays a major role in the survival and growth of cancers with the genetic changes being studied in this clinical trial. RP-6306 is taken orally (by mouth).

Protocol
21-303
Phase
Phase I (phase 1)
Disease Status
Relapsed or Refractory
Investigator
Alison Schram
Co-Investigators
Komal Jhaveri
Chrisann Kyi
Diseases
Solid Tumors
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
ClinicalTrials.gov ID
NCT04855656
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description